Vico Therapeutics – First patient dosed in trial - Ataxia UK

Vico Therapeutics – First patient dosed in trial

Post Published: April 13, 2023

Vico Therapeutics is a company developing therapies for neurological conditions, including some of the SCAs. In April 2023, they announced that they have dosed the first patient in their Phase 1/2a clinical study evaluating VO659 for the treatment of SCA1, SCA3 and Huntington’s Disease (HD). This trial is designed to assess the safety and tolerability of different doses of VO659.

VO659 is a type of therapy called an antisense oligonucleotide (ASO). ASOs target the mutated gene, to prevent it from producing the protein which ultimately causes the condition. In this case, VO659 targets the genes that cause SCA1, SCA3 and HD.

This clinical trial is taking place in sites across Europe, not including the UK.

For more information read the full press release.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top